Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer-Reference-Cited by-同舟云学术

Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer

Published:2020-06-06 Issue:11 Volume:69 Page:2305-2317
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Long Qilai,Ma Ai-Hong,Zhang Hongyong,Cao Zhixiu,Xia Roger,Lin Tzu-Yin,Sonpavde Guru P.,de Vere White Ralph,Guo Jianming,Pan Chong-Xian^ORCID

Funder

National Cancer Institute

U.S. Department of Veterans Affairs

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-020-02609-5.pdf

Reference49 articles.

1. Malumbres M et al (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118(4):493–504

2. Zardavas D, Baselga J, Piccart M (2013) Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 10(4):191–210

3. Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20(13):3379–3383

4. Fry DW et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427–1438

5. Choi YJ, Anders L (2014) Signaling through cyclin D-dependent kinases. Oncogene 33(15):1890–1903

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark;Nature Communications;2024-08-24

2. Improving Dissolution Rate and Solubility of Palbociclib Salts/Cocrystal for Anticancer Efficacy;Journal of Molecular Structure;2024-06

3. CKS2 and Its Interacting Network Induce Tumor Progression with Adverse Effects on Patients' Survival in a Pan-Cancer Model;J BIOL REG HOMEOS AG;2024

4. Mesoporous polydopamine Targeting CDK4/6 Inhibitor toward Brilliant Synergistic Immunotherapy of Breast Cancer;Small;2024-02-23

5. Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review;Frontiers in Oncology;2024-01-24